The much-anticipated results of a trial of more than 800 participants in Japan revealed that, when coupled with standard chemotherapy, the drug panitumumab lowered the risk of death by 18% ...

This has recently led the FDA to approve revisions of the labels for cetuximab and panitumumab noting that the use of these mAbs is not recommended for such patients.